NEW YORK (GenomeWeb) – NanoString Technologies said after the close of the market Tuesday that Canadian regulatory authorities have cleared the firm's Prosigna Breast Cancer Prognostic Gene Signature Assay for marketing.

The Class III Medical Device License from Health Canada clears the Prosigna assay for assessing a woman's 10-year risk of distant recurrence of breast cancer and accurately identifying the intrinsic biologic subtype of the tumor.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.